In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles and influenza before addressing Vincent’s comment on measles inclusion in the clinical respiratory PCR panel, the latest statistics on influenza and COVID-19 circulation, if inflammatory cytokines and anti-viral antibody function synergistically, if administration of peptide agonists of the glucagon-like or sodium-glucose pump can reduce disease severity, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines for SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir or paxlovid can reduce cardiovascular adverse events and the first finding of the two-year longitudinal study on long COVID. For more information about this body of work, listen to TWiV 1088.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Measles tracking (CDC)
• What happens when measles is included in commercial syndromic PCR panels (MMWR)
• Influenza/flu surveillance (CDC)
• Influenza on the Texas ranch (Statnews)
• Sequence analysis of highly pathogenic avian influenza from Texas (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• Can inflammatory cytokines and antibodies play nicely to prevent COVID-19 mortality (IJID)
• Association of GLP-1RA and SGLT-2i to modulate COVID-19 severity (Diabetes Therapy)
• Spring COVID-19 booster recommendations (CIDRAP)
• Older adult spring booster available (CDC)
• Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
• EUA for pemgarda (FDA)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Remdesivir and cardiac adverse events in hospitalized patients (CID)
• Long COVID evidence based review TWiV shout out (TWiV 1088)
• Longitudinal study reveals long COVID symptom peaks and nadirs (OFID)
• Paxlovid lowers risk of cardiovascular disease in COVID-19 patients with autoimmune disease (BMC Medicine)
• Contribute to our ASTMH fundraiser at PWB
• Letters read on TWiV 1102
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]